Abstract Introduction The corticotropin-releasing hormone (CRH) system, its receptors corticotropin-releasing hormone receptor 1 (CRHR1) and 2 (CRHR2), and its corresponding binding protein corticotropin-releasing hormone-binding protein (CRHBP) as well as the urocortin proteins—structural homologues to CRH, which are included in this peptide family—have become interesting oncological targets recently. Carcinogenesis of various human tumors...
02:00
Abstract Introduction In patients undergoing thoracoabdominal aorta repair, spinal cord ischemia (SCI) remains one of the most common and important complications resulting in transient paraparesis through to permanent flaccid paraplegia. In this manuscript, after a brief introduction to spinal cord ischemia complication and its prevention in thoracoabdominal endovascular aortic repair (TEVAR), we propose a new clinical protocol potentially...
Tue Nov 12, 2019 02:00
Hepatoma-derived growth factor (HDGF) participates in angiogenesis and represents a negative prognostic factor in oral cancer. The current study was designed to elucidate the regulatory mechanism between HDGF ... (Source: BMC Cancer)
Mon Nov 11, 2019 01:00
Standardized Nucleic Acid Quantification for SEQuencing (SNAQ-SEQ) is a novel method that utilizes synthetic DNA internal standards spiked into each sample prior to next generation sequencing (NGS) library pre... (Source: BMC Cancer)
Mon Nov 11, 2019 01:00
This study aimed to quantify the associations between full-spectrum changes in body mass index... (Source: BMC Cancer)
Mon Nov 11, 2019 01:00
Elevated red blood cell distribution width (RDW) and decreased platelet count (PLT) can be clinically relevant to the prognosis in cancer patients. However, their prognostic values in patients with diffuse lar... (Source: BMC Cancer)
Mon Nov 11, 2019 01:00
Hepatoma-derived growth factor (HDGF) participates in angiogenesis and represents a negative prognostic factor in oral cancer. The current study was designed to elucidate the regulatory mechanism between HDGF ...
Mon Nov 11, 2019 02:00
CONCLUSION: By this meta-analysis, we found that implementation of DIBH in postoperative radiotherapy for left-side breast cancer can reduce irradiation of heart dose, LADCA dose and left lung dose, without compromising target coverage. PMID: 31707586 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Sat Nov 09, 2019 00:00
CONCLUSIONS: In this study, we found that IMNI improved DFS and OS in breast cancer patients in the context of modern systemic treatment. These data continue to support that IMNI is a key component of RNI. PMID: 31696449 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Wed Nov 06, 2019 00:00
British Journal of Cancer, Published online: 13 November 2019; doi:10.1038/s41416-019-0619-yImpact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
01:59
British Journal of Cancer, Published online: 13 November 2019; doi:10.1038/s41416-019-0632-1Survival after cancer in children, adolescents and young adults in the Nordic countries from 1980 to 2013
01:59
British Journal of Cancer, Published online: 13 November 2019; doi:10.1038/s41416-019-0611-6Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort
01:59
Medical expert witnesses should receive appropriate medicolegal training before they appear in court, new guidance from the Royal College of Surgeons of England advises.1The guidance describes the...
02:30
A Canadian community pharmacist has been recognised by the UK charity Sense About Science for enduring a “barrage of harassment” from alternative practitioners when he persisted in speaking out...
Tue Nov 12, 2019 22:00
General practice hit the headlines this week when the Conservatives promised to deliver 6000 more GPs by 2024-25 as part of a pledge to provide 50 million more appointments in GP surgeries every...
Tue Nov 12, 2019 19:21
A Nottinghamshire paediatrician has reported a severe immune reaction in a 16 year old boy who had been smoking e-cigarettes. The incident comes amid growing concerns at the safety of the products,...
Tue Nov 12, 2019 13:26
Some 250 doctors and 350 nurses at the New Karolinska Hospital (NKS) in Stockholm have been warned that they could lose their jobs because of an unexpected deficit of SEK1.6bn (£128m; €150m; $165m)...
Tue Nov 12, 2019 16:41
The recent case of Radhakrishna Shanbhag, a senior trauma and orthopaedic surgeon who was asked by a patient if a white doctor could do his operation instead, has hit the headlines.1 It shines a...
Tue Nov 12, 2019 15:56
Smith and colleagues describe widespread opioid prescribing and use in European and North American countries.1 The editorial, however, neglects some important factors, such as the contribution of...
Tue Nov 12, 2019 14:36
Smith and colleagues say that opioid prescribing is rising in many countries,1 with the result that use is “widespread.” While this may be true in high income countries, we must remember that lack of...
Tue Nov 12, 2019 14:31
Once again the UK has recorded its highest rate of drug related deaths—this is the seventh annual increase we have witnessed. The number of people dying is now at unprecedented levels, which has led...
Tue Nov 12, 2019 14:16
Mali is a vast and troubled country. Much of it is lawless Sahara desert, where UN peacekeepers have failed in recent years to root out jihadists and criminal gangs. To the south, where the Sahara...
Tue Nov 12, 2019 14:15
Patients arrive at a GP appointment with all manner of symptoms and varying degrees of unease, anxiety, pain, and fear. If we aim for patients to leave feeling better than when they came, they need...
Tue Nov 12, 2019 14:06
As I walk towards the sound of 1970s music, coloured disco lights spill out from the window. I clutch a quickly wrapped bottle of cold wine, snatched from the fridge as I left the house. But an early...
Tue Nov 12, 2019 14:05
The chief medical officer’s report on childhood obesity has helped to raise awareness of one of the most serious public health challenges of the 21st century.12 It describes evidence that shows that...
Tue Nov 12, 2019 13:36
Background The objective of this study was to conduct the first systematic evaluation of the long‐term economic impact of arsenic trioxide (ATO) plus all‐trans retinoic acid (ATRA) for the treatment of patients with newly diagnosed acute promyelocytic leukemia (APL) from the perspective of the Chinese health care system. Methods On the basis of clinical data from a randomized phase 3 trial, a time‐dependent Markov model with 4 health states (complete remission, relapse or treatment failure,...
Tue Nov 12, 2019 16:15
Tue Nov 12, 2019 16:14
AbstractRacial/ethnic disparities in cancer outcomes have been well documented. Access to Pap testing may account for some of the variation in the racial and socioeconomic differences in cervical cancer outcomes. Literature exploring perceived access to care as it relates to women of color and low-income women is lacking. The goal of the study was to evaluate and characterize the relationship between what respondents believe about access to free/low-cost screening facilities and screening behaviors...
Tue Nov 12, 2019 00:00
Publication date: 11 November 2019Source: Cancer Cell, Volume 36, Issue 5Author(s): Xue-Yan He, David Ng, Linda Van Aelst, Mikala EgebladStress has long been suspected to negatively influence cancer mortality, yet the molecular mechanisms responsible for this effect have only recently been identified. A new study identifies a stress-induced response in dendritic cells—the activation of the glucocorticoid-inducible transcriptional regulator TSC22D3—as a potent, immunosuppressive effect of stress on...
Tue Nov 12, 2019 22:38
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Publication date: 11 November 2019Source: Cancer Cell, Volume 36, Issue 5Author(s): Rachel Grosser, Leonid Cherkassky, Navin Chintala, Prasad S. AdusumilliCheckpoint blockade (CPB) therapy can elicit durable clinical responses by reactivating an exhausted immune response. However, response rates remain limited, likely secondary to a lack of a tumor-reactive immune infiltrate. Chimeric antigen receptor (CAR) T cells may provide the necessary tumor-targeting immune infiltrate and a highly specific...
Tue Nov 12, 2019 22:38
Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy
Publication date: 11 November 2019Source: Cancer Cell, Volume 36, Issue 5Author(s): Jessica L. Hopkins, Lee ZouIn this issue of Cancer Cell, Quereda and colleagues report that a newly developed specific inhibitor of CDK12/13, SR-4835, sensitizes triple-negative breast cancer cells to PARP inhibitors and DNA-damaging chemotherapeutics by reducing expression of the genes in the DNA damage response pathway. (Source: Cancer Cell)
Tue Nov 12, 2019 22:38
Publication date: 11 November 2019Source: Cancer Cell, Volume 36, Issue 5Author(s): Lisa N. Heppler, David A. FrankDespite the role of STAT3 as a known driver of oncogenesis, efforts to develop therapeutic STAT3 inhibitors have thus far been unsuccessful. In this issue of Cancer Cell, Bai et al. report a potent and selective STAT3 degrader capable of producing complete and long-lasting tumor regression in mouse xenograft models. (Source: Cancer Cell)
Tue Nov 12, 2019 22:38
Publication date: 11 November 2019Source: Cancer Cell, Volume 36, Issue 5Author(s): Anthony M. Joshua, Ian F. TannockIn this issue of Cancer Cell, Pillarsetty and colleagues radiolabel the potential anticancer drug PU-H71 and use it with PET imaging to quantify the epichaperome protein complex in tumors and its inhibition by the drug. They thereby develop a companion diagnostic paradigm of probe-drug pairing to explore therapeutic potential. (Source: Cancer Cell)
Tue Nov 12, 2019 22:38
Publication date: 11 November 2019Source: Cancer Cell, Volume 36, Issue 5Author(s): Longchuan Bai, Haibin Zhou, Renqi Xu, Yujun Zhao, Krishnapriya Chinnaswamy, Donna McEachern, Jianyong Chen, Chao-Yie Yang, Zhaomin Liu, Mi Wang, Liu Liu, Hui Jiang, Bo Wen, Praveen Kumar, Jennifer L. Meagher, Duxin Sun, Jeanne A. Stuckey, Shaomeng WangSummarySignal transducer and activator of transcription 3 (STAT3) is an attractive cancer therapeutic target. Here we report the discovery of SD-36, a small-molecule...
Tue Nov 12, 2019 22:38
Publication date: 11 November 2019Source: Cancer Cell, Volume 36, Issue 5Author(s): Anne Trinh, Kornelia PolyakImmunotherapy has been the most effective in tumors with high mutational burden. However, a recent study in Cell by Wolf et al. demonstrates that high intratumor heterogeneity (ITH) for cancer neoantigens paradoxically attenuates anti-tumor immune responses, suggesting a need to quantify ITH to improve patient selection for checkpoint blockade therapy. (Source: Cancer Cell)
Tue Nov 12, 2019 22:38
Men with low‐risk prostate cancer are at risk for making decisions based on misconceptions about treatment options and outcomes. A decision support intervention, delivered by premedical students acting as health coaches, increased patient knowledge of key facts about prognosis. Abstract Objectives Development and pilot evaluation of a personalized decision support intervention to help men with early‐stage prostate cancer choose among active surveillance, surgery, and radiation. Methods...
Tue Nov 12, 2019 22:00
Local tumor progression (LTP) is a key criterion for evaluating the technical success of various thermal ablation techniques. Insufficient ablation margin is an independent risk factor associated with LTP, however, it is difficult to measure accurately. This normogram demonstrated higher predictive accuracy compared with traditional staging systems and may prove to be useful in centers that do not have the facilities for measuring ablation margin. Abstract Objectives To develop a nomogram for...
Tue Nov 12, 2019 17:50
In this study, we show that different TKIs used for treatment of Chronic Myeloid Leukemia have opposing effects on platelet function, with large inter‐individual differences. Thus, in patients with high risk for hemostatic or thrombotic complications, we suggest that treatment with TKIs should be individualized to minimize risks associated with long‐term treatment. Abstract Since their introduction, tyrosine kinase inhibitors (TKIs, eg, imatinib, nilotinib, dasatinib, bosutinib, ponatinib) have...
Tue Nov 12, 2019 13:40
Multiple myeloma (MM) is currently considered to be incurable. For the first time, we show that an inhibitor of T‐LAK cell‐originated protein kinase suppressed several MM‐supportive pathways and induced potent MM‐selective killing that synergized with a common component of current treatment regimens, making OTS514 a suitable candidate for targeting in a clinical setting. Abstract Multiple myeloma (MM) continues to be considered incurable, necessitating new drug discovery. The mitotic kinase T‐LAK...
Tue Nov 12, 2019 11:05
Human papillomavirus (HPV) attributable cancer burden is currently unknown in China; we estimated HPV‐attributable cancer cases and deaths by sex, cancer site, age and geographical area. There is a pressing need for these data to inform evidence‐based policy with regard to HPV vaccination and screening programs. Abstract Background Human papillomavirus (HPV) attributable cancer burden is currently unknown in China, which is essential to evaluate the potential benefit of existing HPV vaccines...
Tue Nov 12, 2019 11:04
Local and metastatic relapse of prostate cancer often occur following attempted curative resection of the primary tumor and up to 66% of local recurrences are associated with positive margins. Therefore, technologies that can improve the visualization of tumor margins and adjuvant therapies to ablate remaining tumor tissues are needed during surgical resection of prostate adenocarcinoma. Photodynamic agents have the potential to combine both fluorescence for image-guided surgery (IGS) and photodynamic...
Tue Nov 12, 2019 16:30
Li-Fraumeni syndrome (LFS) is a rare hereditary cancer syndrome associated with an autosomal dominant mutation inheritance in the TP53 tumor suppressor gene and a wide spectrum of cancer diagnoses. The previously developed R package, LFSPRO, is capable of estimating the risk of an individual being a TP53 mutation carrier. However, an accurate estimation of the penetrance of different cancer types in LFS is crucial to improve the clinical characterization and management of high-risk individuals. Here,...
Tue Nov 12, 2019 16:30
Li-Fraumeni syndrome (LFS) is a rare autosomal dominant disorder associated with TP53 germline mutations and an increased lifetime risk of multiple primary cancers (MPC). Penetrance estimation of time to first and second primary cancer within LFS remains challenging due to limited data and the difficulty of characterizing the effects of a primary cancer on the penetrance of a second primary cancer. Using a recurrent events survival modeling approach that incorporates a family-wise likelihood to efficiently...
Tue Nov 12, 2019 16:30
Inhibition of the androgen receptor (AR) is the main strategy to treat advanced prostate cancers. AR-independent treatment-resistant prostate cancer is a major unresolved clinical problem. Prostate cancer patients with alterations in canonical WNT pathway genes, which lead to β-catenin activation, are refractory to AR-targeted therapies. Here using clinically relevant murine prostate cancer models, we investigated the significance of β-catenin activation in prostate cancer progression and treatment...
Tue Nov 12, 2019 16:30
Abstract This study was designed to evaluate the dynamic survival and recurrence of remnant gastric cancer (RGC) after radical resection and to provide a reference for the development of personalized follow‐up strategies. A total of 298 patients were analysed for their 3‐year conditional overall survival (COS3), 3‐year conditional disease‐specific survival (CDSS3), corresponding recurrence and pattern changes, and associated risk factors. The 5‐year OS and the 5‐year DSS of the entire cohort were...
Mon Nov 11, 2019 15:44
Urothelial carcinomas (UC) are immunogenic tumors against which immunotherapeutic approaches have shown substantial clinical benefit [1]. Despite their immunogenicity, tumors can evade the immune system by a variety of means, including altered expression of proteins that act within the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway to suppress T-cell antitumor activity [1 –3]. PD-L1 is highly expressed on the surface of activated T cells in response to inflammation...
Mon Nov 11, 2019 00:00
Rectal cancers account for 39% of colorectal tumours, and represent the 8th most common malignancy and the 9th leading cause of cancer-related deaths [1]. In 2018, 704,376 new diagnoses and 310,394 deaths for this disease were registered worldwide [1]. The global distribution of rectal cancer is characterised by some geographic variation with incidence rates being higher in Eastern Europe, Australia/New Zealand and Eastern Asia while lower in most African regions and Southern Asia [1]. Rectal cancers...
Mon Nov 11, 2019 00:00
Pancreatic adenocarcinoma (PDAC) is the most common type of pancreatic cancer (PC) [1 –3]. PDAC incidence is rising; it is expected to become the second cause of cancer-related death by 2030 and has a very poor prognosis[4]. More than 80% of patients have an advanced disease at diagnosis, and the 5-year overall survival rate is approximately 7% [5]. Poor survival is attributed to h igh aggressiveness, intrinsic chemotherapeutics resistance and lack of effectively targetable oncogenic drivers. Systemic...
Mon Nov 11, 2019 00:00
Multiple myeloma (MM) is an incurable plasma cell dyscrasia characterized by the uncontrollable proliferation of clonal plasma cells resulting in myeloma-defining events (end-organ damage and/or biomarkers of malignancy) [1]. MM constitutes a significant contributor to the global burden of hematological malignancy causing 2.1 million disability-adjusted life-years (DALYs) worldwide according to the Global Burden of Disease 2016 study [2]. During the last decades, an increase in the disease incidence...
Mon Nov 11, 2019 00:00
Prostate cancer (PCa) is the most prevalent cancer in men and one of the predominant causes of death among men in European countries [1]. While most PCa remain localized, a subset will be aggressive, leading to metastasis formation associated with significant morbidity and mortality. Thus, one major issue in PCa research is to early detect those patients who are likely to harbor an aggressive variant of PCa at young age importantly needing an active anti-cancer treatment. (Source: Cancer Treatment...
Mon Nov 11, 2019 00:00
Recently, immune checkpoint therapy was shown to be very effective in the treatment of several cancers by reactivating the immune system. This was also shown for hard to treat cancers such as melanoma and lung cancer. At the forefront of immune checkpoint therapy are antibodies targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and the programmed cell death-1 (PD-1). However, clinical success of immune checkpoint inhibitors greatly varies between different cancer types, ranging from objective...
Mon Nov 11, 2019 00:00
Jason Williams, MD, discusses the development of intratumoral immunotherapy, as well as trial results from his poster presentation at the 34th Annual Meeting& Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019). (Source: CancerNetwork)
Tue Nov 12, 2019 06:00
Joshua Brody, MD, discusses the gratification of the crossover between medicine and science at the 34th Annual Meeting& Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019). (Source: CancerNetwork)
Tue Nov 12, 2019 06:00
In our lung cancer quiz, you'll get a chance to test your knowledge of the management of sarcopenia in patients with lung cancer. (Source: CancerNetwork)
Tue Nov 12, 2019 06:00
Researchers have opened an expansion cohort to include patients with mantle cell lymphoma in the phase I/II CIRLL study to determine if adding cirmtuzumab to ibrutinib can increase the rate of complete remissions. (Source: CancerNetwork)
Tue Nov 12, 2019 06:00
Cancers, Vol. 11, Pages 1781: Radiation and Stemness Phenotype May Influence Individual Breast Cancer Outcomes: The Crucial Role of MMPs and Microenvironment Cancers doi: 10.3390/cancers11111781 Authors: María Auxiliadora Olivares-Urbano Carmen Griñán-Lisón Sandra Ríos-Arrabal Francisco Artacho-Cordón Ana Isabel Torralbo Elena López-Ruiz Juan Antonio Marchal María Isabel Núñez Breast cancer is the most common cancer in women. Radiotherapy (RT) is one of the mainstay...
Tue Nov 12, 2019 02:00
Cancers, Vol. 11, Pages 1780: Prognostic Factors in a Large Nationwide Cohort of Histologically Confirmed Primary and Secondary Angiosarcomas Cancers doi: 10.3390/cancers11111780 Authors: Marije E. Weidema Uta E. Flucke Winette T.A. van der Graaf Vincent K.Y. Ho Melissa H.S. Hillebrandt-Roeffen Dutch Nationwide Network and Registry of Histo- and Cytopathology (PALGA)-Group Dutch Nationwide Network and Registry of Histo- and Cytopathology (PALGA)-Group Yvonne M.H. Versleijen-Jonkers...
Tue Nov 12, 2019 02:00
Purpose: We aimed to investigate genomic correlates underlying extremes of survivorship in metastatic colorectal cancer (CRC) and their applicability in informing survival in distinct subsets of metastatic CRC patients. Experimental Design: We examined differences in oncogenic somatic alterations between metastatic CRC cohorts demonstrating extremes of survivorship following complete metastasectomy: ≤2-year (n=17) and ≥10-year (n=18) survivors. Relevant genomic findings, and their association with...
Tue Nov 12, 2019 15:51
Purpose: A cryptic inv(16)(p13.3q24.3) encoding the CBFA2T3-GLIS2 fusion is associated with poor outcome in infants with acute megakaryocytic leukemia. We aimed to broaden our understanding of the pathogenesis of this fusion through transcriptome profiling. Experimental Design: Available RNA from children and young adults with de novo AML (N=1,049) underwent transcriptome sequencing (mRNA and miRNA). Transcriptome profiles for those with the CBFA2T3-GLIS2 fusion (N=24) and without (N=1,025) were...
Tue Nov 12, 2019 15:51
Future Oncology, Ahead of Print.
Tue Nov 12, 2019 06:17
Related ArticlesXRCC1 632 as a candidate for cancer predisposition via a complex interaction with genetic variants of base excision repair and double strand break repair genes. Future Oncol. 2019 Nov 11;: Authors: Singh A, Singh N, Behera D, Sharma S Abstract Aim: The DNA repair system safeguards integrity of DNA. Genetic alterations force the improper repair which in conjugation with other factors ultimately results in carcinogenesis. Materials &...
Tue Nov 12, 2019 17:42
Related ArticlesSurvival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. Future Oncol. 2019 Nov 11;: Authors: Rossi S, Finocchiaro G, Noia VD, Bonomi M, Cerchiaro E, Rose F, Franceschini D, Navarria P, Ceresoli GL, Beretta GD, D'Argento E, Scorsetti M, Santoro A, Toschi L Abstract Aim: The association of tyrosine kinase inhibitors (TKIs) and local radiotherapy...
Tue Nov 12, 2019 17:42
Related ArticlesReal-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study. Future Oncol. 2019 Nov 11;: Authors: Gallagher JR, Heap KJ, Carroll S, Travers K, Harrow B, Westin SN Abstract Aim: To assess real-world occurrence of common clinical trial-reported adverse events (AE) among patients with recurrent ovarian cancer initiating niraparib 200 mg/day. Materials & methods: This retrospective...
Tue Nov 12, 2019 13:48
In Ethiopia, most cervical cancer patients present at advanced cancer stages, long time after they experience first symptoms. We investigated possible predictors of long time spans between symptom onset and pa... (Source: Infectious Agents and Cancer)
Mon Nov 11, 2019 01:00
CONCLUSION: Our meta-analysis indicates when compared with control group, the PD-1/PD-L1 inhibitors may lead to a higher risk of all grade and high grade immune-mediated colitis, but may result in a reduction in all grade diarrhea. PD-1 inhibitors in NSCLC patients, but not PD-L1 inhibitors, increase the risk of all- and high grade colitis. These results suggest that clinicians shall pay more attention to this rare but life-threatening toxic effect. PMID: 31704288 [PubMed - as supplied by publisher]...
Tue Nov 05, 2019 00:00
CONCLUSIONS: The clinical roles of PD-1/PD-L1 expression vary between subtypes of lymphoma. Future studies should delineate the prognostic and predictive roles of PD-1 and PD-L1 expression. PMID: 31704289 [PubMed - as supplied by publisher] (Source: International Immunopharmacology)
Tue Nov 05, 2019 00:00
In this study, we attempted to evaluate the potential impact of Tan IIA on the skin fibrosis-related endothelial-to-mesenchymal transition (EndoMT) and investigate the underlying molecular mechanisms. EndoMT-related indexes including morphological characteristics, functional changes, histological parameters, expression levels of extracellular matrix associated genes, and changes in the expression of related biomarkers in dermal fibrosis were assessed. Tan IIA had a strong anti-fibrotic effect through...
Tue Nov 05, 2019 00:00
In conclusion, the findings indicate that pinocembrin treatment decreases autonomic remodeling, lowers atrial fibrosis, ameliorates atrial electrical remodeling, and suppresses MI-induced inflammatory responses, which suggests a potential novel strategy for atrial arrhythmias. PMID: 31704291 [PubMed - as supplied by publisher] (Source: International Immunopharmacology)
Tue Nov 05, 2019 00:00
Authors: Xu Z, Yang H, Zhou X, Li J, Jiang L, Li D, Wu L, Huang Y, Xu N Abstract The mTOR signaling pathway has been demonstrated to be related to the development of osteoarthritis (OA) by regulating expression of autophagy regulators. Few studies have shed light on the association of mTOR-pathway-related gene variants with OA risk. Totally 441 OA patients and 533 controls were recruited and their genotypes for mTOR-pathway-related gene variants were determined based on the matrix-assisted...
Tue Nov 05, 2019 00:00
In this study, we investigated the possible protective effects of Ferulic acid (FA) against benzo(a)pyrene (BaP)-induced microglial activation using BV2 cells as the model system. Exposure of BV2 cells to BaP (10 μM) significantly increased DNA damage and the production of pro-inflammatory mediators, including nitric oxide (NO), inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), reactive oxygen species (ROS), malondialdehyde (MDA), and cytokines (interleukins-1β and -6). On the other...
Mon Nov 04, 2019 00:00
In conclusion, increased awareness of nivolumab-related hypercalcemia -an extremely rare immune-related adverse event- could enable the identification of immune-related elevation of PTHrP. Moreover, our cases provide the rationale for further research in pursuit of not only the source of immune-related PTHrP expression, but also of a causative link connecting the inflammatory milieu of immune-related pneumonitis and/or immune-related colitis with PTHrP-mediated hypercalcemia. Finally, the correlation...
Mon Nov 04, 2019 00:00
Tue Nov 12, 2019 02:00
Overexpressed PES1 promotes carcinogenesis in various types of malignant tumors. However, the biological role and clinical significance of PES1 in pancreatic cancer are still unexplored.
Tue Nov 12, 2019 02:00
Long non-coding RNAs (lncRNAs) are tumor-associated biological molecules and have been found to be implicated in the progression of colorectal cancer (CRC). This study aims to examine the effects of lncRNA RP1...
Tue Nov 12, 2019 02:00
Circular RNAs (circRNAs) have recently been shown to play important roles in different tumors. However, their detailed roles and regulatory mechanisms in pancreatic ductal adenocarcinoma (PDAC) are not well un...
Tue Nov 12, 2019 02:00
Prostate cancer (PCa) is a leading cause of cancer-related death in males worldwide. Exacerbated inflammation and angiogenesis have been largely demonstrated to contribute to PCa progression. Diverse naturally...
Tue Nov 12, 2019 02:00
We investigated the role of PD-L1 in the metabolic reprogramming of non-small cell lung cancer (NSCLC).
Tue Nov 12, 2019 02:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου